Saturday, May 31, 2025

Latest

Cresco Labs Reports Q4 2020 Revenues Of $162.3 Million, Net Loss Of $23.4 Million

Cresco Labs (CSE: CL) this morning reported its fourth quarter and full year 2020 financial results. The company recorded fourth quarter revenues of $162.3 million, along with a net loss of $23.4 million. For the full year, revenues came in at $476.3 million, while the company posted a net loss of $36.6 million.

The fourth quarter saw the company beat consensus estimates for revenue, which sat at $161.38 million, while also beating on adjusted EBITDA, which was estimated at $48.06 million, compared to the $50.0 million realized by the company. Full year results also beat consensus on both measures, with revenue consensus sitting at $475.5 million and adjusted EBITDA consensus at $114.12 million. The company reported full year adjusted EBITDA of $116.0 million.

Looking at the fourth quarter, revenues grew from $153.3 million in the third quarter to $162.3 million in the fourth. Cost of sales amounted to $89.3 million, resulting in a gross profit before fair value adjustments of $73.0 million. Post-fair value adjustments the firm saw gross profit jump to $95.7 million, which the company pegged as being a 59.0% margin, compared to 55.2% in the prior quarter.

Total expenses meanwhile amounted to $73.7 million, with SG&A amounted to $68.1 million, a significant climb from the $46.8 million recorded in the third quarter. Depreciation and amortization amounted to a further $5.6 million in expenditures.

Other expenses of $31.1 million ultimately put the company in the red. Cresco recognized $10.4 million in interest expenses during the quarter, while other expenses hit $19.8 million, resulting in a net loss of $23.4 million overall for the quarter.

Full financials have yet to be filed for the quarter, with a brief snapshot being provided for the balance sheet. Cash and cash equivalents for the quarter amounted to $136.3 million, a notable improvement from the $57.7 million recorded in the third quarter. Total current assets overall improved from $257.1 million to $361.8 million. To current liabilities meanwhile declined from $243.7 million to $194.6 million.

Cresco Labs last traded at $16.46 on the CSE.


Information for this briefing was found via Sedar and the companies mentioned. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Leave a Reply

Video Articles

Cerrado Gold Q4 Earnings: The Turnaround is Working

B2GOLD Q1 Earnings: Revenue Up, Production & Cash Flow Decline

Canadian Copper: The $172M Combined Strategy PEA

Recommended

Canadian Copper: The $172M Combined Strategy PEA

ESGold Begins Concentration Tests Ahead Of First Production

Related News

The Influence of Branding Within the US Cannabis Sector

Brands dominate in the US. Thus, its only natural that a heavy branding strategy has...

Wednesday, April 17, 2019, 12:30:08 PM

Cresco Labs Enters US$282.5 Million Purchase Agreement for Tryke Companies

Cresco Labs (CSE: CL) announced this morning that it has entered a purchase agreement to...

Monday, September 16, 2019, 09:08:24 AM

Cresco Labs Receives Regulatory Approval in New York

Cresco Labs (CSE: CL) announced this morning that it had received regulatory approval to proceed...

Thursday, August 8, 2019, 11:34:03 AM

Cresco Labs: Canaccord Cuts Price Target On Muted Growth, Pricing Challenges

On August 17, Cresco Labs (CSE: CL) reported its second quarter financial results. The company...

Friday, August 19, 2022, 02:12:00 PM

Cresco Labs President Joe Caltabiano Resigns Effective Immediately

Cresco Labs (CSE: CL) has seen one of its co-founders resign as of this morning....

Tuesday, March 3, 2020, 08:39:14 AM